The field of pharmacogenomics (PGx) is gradually shifting from the reactive testing of single
genes toward the proactive testing of multiple genes to improve treatment outcomes, reduce …

Background Pathogenic variants of the DPYD gene are strongly associated with grade≥ 3
toxicity during fluoropyrimidine chemotherapy. We conducted a systematic review and meta …

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)
for Colon Cancer focuses on systemic therapy options for the treatment of metastatic …

Pharmaceuticals have extensive reciprocal interactions with the microbiome, but whether
bacterial drug sensitivity and metabolism is driven by pathways conserved in host cells …

Background Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients
and is often the result of reduced activity of the key metabolic enzyme dihydropyrimidine …

Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx …

Abstract The Dutch Pharmacogenetics Working Group (DPWG) guideline presented here,
presents the gene-drug interaction between the genes CYP2C19 and CYP2D6 and …

Background: 5-Fluorouracil (FU) is one of the most commonly used cytostatic drugs in the
systemic treatment of cancer. Treatment with FU may cause severe or life-threatening side …

Fluoropyrimidines (fluorouracil, capecitabine, and other analogs) are highly used anticancer
drugs worldwide. However, patients with cancer treated with these drugs might experience …

Background Adjuvant fluoropyrimidine-based chemotherapy substantially reduces
recurrence and mortality after resection of stage 3 colon cancer. While standard doses of 5 …